Intranasal ketamine — Competitive Intelligence Brief

Intranasal ketamine (Intranasal ketamine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist. Area: Psychiatry / Pain Management.

marketed NMDA receptor antagonist NMDA receptor Psychiatry / Pain Management Small molecule

Target snapshot

Intranasal ketamine (Intranasal ketamine) — Rhode Island Hospital. Intranasal ketamine is a rapid-acting NMDA receptor antagonist that blocks glutamate signaling in the brain to produce fast-onset antidepressant and analgesic effects.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intranasal ketamine TARGET	Intranasal ketamine	Rhode Island Hospital	marketed	NMDA receptor antagonist	NMDA receptor
Namenda	MEMANTINE	AbbVie	marketed	N-methyl-D-aspartate Receptor Antagonist	Glutamate NMDA receptor; GRIN1/GRIN2A	2003-01-01
Felbatol	FELBAMATE	Mylan Speciality Lp	marketed	Anti-epileptic Agent [EPC]	NMDA receptor-ionophore complex	1993-01-01
QUINIDINE	QUINIDINE		marketed		sigma-1 receptor, NMDA receptor, CYP2D6	1950-01-01
Methadone Hydrochloride	METHADONE	Specgx Llc	marketed	Opioid Agonist	mu-opioid receptors, NMDA receptor	1947-01-01
Rémifentamil + KETAMINE	Rémifentamil + KETAMINE	University Hospital, Clermont-Ferrand	marketed	Opioid + NMDA receptor antagonist combination	Mu-opioid receptor (remifentanil); NMDA receptor (ketamine)
Oxygen/nitrous oxide equimolar mix	Oxygen/nitrous oxide equimolar mix	Hospital St. Joseph, Marseille, France	marketed	Inhalational anesthetic/analgesic gas mixture	NMDA receptor antagonist; endogenous opioid system modulation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist class)

1. Turku University Hospital · 3 drugs in this class
2. H. Lundbeck A/S · 2 drugs in this class
3. Ciusss de L'Est de l'Île de Montréal · 2 drugs in this class
4. Shalvata Mental Health Center · 2 drugs in this class
5. New York State Psychiatric Institute · 2 drugs in this class
6. Auris Medical AG · 1 drug in this class
7. AstraZeneca · 1 drug in this class
8. Alameda Health System · 1 drug in this class
9. Centre Hospitalier Universitaire de Nice · 1 drug in this class
10. Asker & Baerum Hospital · 1 drug in this class